MNOV MediciNova Inc.

+0.19  (+2%)
Previous Close 8
Open 8.2
Price To Book 4.73
Market Cap 345387124
Shares 42,171,810
Volume 23,820
Short Ratio
Av. Daily Volume 52,377

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released October 28, 2017 at Joint ECTRIMS – ACTRIMS meeting. Primary endpoint met.
Progressive multiple sclerosis (progressive MS)
Phase 2 abstract presented at EASL April 13, 2018. Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint of cholesterol efflux capacity not released).
NASH (nonalcoholic steatohepatitis)
Phase 2 data released March 29, 2018 - primary endpoint not met.
Methamphetamine dependence
Phase 2a trial fully enrolled - noted July 30, 2018. Data due 2019.
Amyotrophic lateral sclerosis (ALS)
Phase 2/3 trial initiation announced August 6, 2018.
MN-166 (ibudilast)
Degenerative cervical myelopathy (DCM)
Phase 2 initiation announced January 8, 2019.

Latest News

  1. MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania
  2. MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan
  3. MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports
  4. MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS…
  5. One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price
  6. MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases
  7. The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study
  8. MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma
  9. MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
  10. Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)?
  11. MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco
  12. MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy…
  13. The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
  14. MNOV: Positive FDA Feedback on ALS Phase 3 Plan…